3.5-二氯-4-羟基苯甲酸甲酯 | 3337-59-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3.5-二氯-4-羟基苯甲酸甲酯
• 中文别名: ,5-二氯-4-羟基苯甲酸甲酯；3,5-二氯-4-羟基苯甲酸甲酯；5-二氯-4-羟基苯甲酸甲酯
• 英文名称: methyl 3,5-dichloro-4-hydroxybenzoate
• 英文别名: methyl 4-hydroxy-3,5-dichloro-benzoate
• CAS: 3337-59-5
• 化学式: C₈H₆Cl₂O₃
• mdl: MFCD00016419
• 分子量: 221.04
• InChiKey: UKMOOQFHBGTLAO-UHFFFAOYSA-N

物化性质

• 熔点：
  122-125°C
• 沸点：
  340.99°C (rough estimate)
• 密度：
  1.4760 (rough estimate)
• 稳定性/保质期：

  在常温常压下，该物质保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn,F,Xi
• WGK Germany：
  3
• 海关编码：
  2918290000
• 安全说明：
  S16,S26,S36,S36/37/39
• 危险类别码：
  R20/21/22,R10,R36/37/38
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  常温、避光、通风干燥处，密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3,5-dichloro-4-hydroxybenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3,5-dichloro-4-hydroxybenzoate
CAS number: 3337-59-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6Cl2O3
Molecular weight: 221

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3.5-二氯-4-羟基苯甲酸甲酯 在 氯化亚砜 、 potassium carbonate 、 sodium iodide 作用下， 以 various solvent(s) 为溶剂， 反应 68.0h， 生成 5-{5-[2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy]pentyl}-3-methylisoxazole
  参考文献：
  名称：

  一些二取代的苯基异恶唑类抗人小核糖核酸病毒的合成及结构活性研究。

  摘要：

  已经制备了广谱抗小核糖核酸病毒药物二恶草腈的许多2，6-二取代类似物，并针对几种鼻病毒血清型进行了评估。QSAR的一项研究表明，针对五种鼻病毒血清型的平均MIC（MIC）与log P密切相关。2,6-二氯类似物15在体外对MIC80为0.3 microM的鼻病毒非常有效，对几种肠病毒，并且在预防感染柯萨奇A-9的小鼠中也有效地预防了麻痹。

  DOI：

  10.1021/jm00122a027
• 作为产物：
  描述：

  对羟基苯甲酸甲酯 在 N-氯代丁二酰亚胺 、 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以65%的产率得到3.5-二氯-4-羟基苯甲酸甲酯
  参考文献：
  名称：

  [EN] ORGANIC COMPOUNDS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  揭示了新型苯并呋喃衍生物。这些衍生物具有S1P1受体活性和/或疾病修饰活性，并可用于治疗与动物和/或人类的免疫、血管和神经系统相关的疾病或症状。

  公开号：

  WO2014063199A1

文献信息

• Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful
  申请人：Sterling Drug Inc.

  公开号：US04857539A1

  公开（公告）日：1989-08-15

  Compounds of the formula ##STR1## wherein: Y is an alkylene bridge of 3-9 carbon atoms; Z is N or HC; R is hydrogen or lower-alkyl of 1-5 carbon atoms, with the proviso that when Z is N, R is lower-alkyl; R.sub.1 and R.sub.2 are hydrogen, halogen, lower-alkyl, lower-alkoxy, nitro, lower-alkoxycarbonyl or trifluoromethyl; and Het is selected from specified heterocyclic groups, are useful and antiviral agents, particularly against picornaviruses, including numerous strains of rhinovirus.

  化合物的公式为##STR1##其中：Y是3-9个碳原子的烷基桥；Z是N或HC；R是氢或1-5个碳原子的低烷基，但当Z是N时，R是低烷基；R.sub.1和R.sub.2是氢、卤素、低烷基、低烷氧基、硝基、低烷氧羰基或三氟甲基；Het从指定的杂环基团中选择，对抗病毒剂，特别是对抗小RNA病毒，包括多种鼻病毒菌株。
• 4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist
  作者：Jun Chiba、Shin Iimura、Yoshiyuki Yoneda、Yuichi Sugimoto、Takao Horiuchi、Fumito Muro、Yuichi Ochiai、Tomomi Ogasawara、Masao Tsubokawa、Yutaka Iigou、Gensuke Takayama、Tomoe Taira、Yoshimi Takata、Mika Yokoyama、Tohru Takashi、Atsushi Nakayama、Nobuo Machinaga

  DOI：10.1248/cpb.54.1515

  日期：——

  A novel series of benzoic acid derivatives as VLA-4 antagonists were synthesized. Optimization, focusing on activity and lipophilicity needed for cell permeability, resulted in the identification of 15b and 15e with good activity (IC50=1.6 nM each) and moderate lipophilicity (Log D=2.0, 1.8). Furthermore, 15e demonstrated efficacy in murine asthma model by an oral dose of 30 mg/kg.

  合成了一系列苯甲酸衍生物作为VLA-4拮抗剂。优化侧重于活性和细胞通透性所需的亲脂性，最终鉴定出活性良好（IC50分别为1.6纳摩尔）和适度亲脂性（Log D=2.0，1.8）的化合物15b和15e。此外，化合物15e在30毫克/千克口服剂量下对小鼠哮喘模型显示出疗效。
• [EN] (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS<br/>[FR] CARBOXYLATES PROPANOIQUES 3,4-DISUSBSTITUES UTILISES EN TANT QU'AGONISTES DU RECEPTEUR S1P (EDG)
  申请人：MERCK & CO INC

  公开号：WO2005058848A1

  公开（公告）日：2005-06-30

  The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖了化合物A的公式：A以及其药用可接受的盐。这些化合物是S1P1/Edg1受体激动剂，因此通过调节白细胞的运动、在次生淋巴组织中滞留淋巴细胞以及增强血管完整性而具有免疫抑制、抗炎和止血活性。该发明还涉及含有这些化合物的药物组合物以及治疗或预防的方法。
• Angiotensin II antagonists incorporating a substituted pyridoimidazolyl
  申请人：Merck & Co., Inc.

  公开号：US05240938A1

  公开（公告）日：1993-08-31

  Substituted heterocycles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I are useful as angiotensin II antagonists. ##STR1##

  通过一个亚甲基桥连接到新的取代苯基衍生物的取代杂环对式I的化合物可作为血管紧张素II拮抗剂。
• Six membered ring fused imidazoles substituted with phenoxyphenylacetic
  申请人：Merck & Co., Inc.

  公开号：US05374638A1

  公开（公告）日：1994-12-20

  Phenoxyphenylacetic acids and derivatives of general structural formula I ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, congestive heart failure, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, inflammatory diseases, Raynaud's disease, and endotoxic shock, and asthma.

  苯氧苯乙酸及其一般结构式I的衍生物具有内皮素拮抗活性，因此在治疗心血管疾病，如高血压、充血性心力衰竭、缺血后肾功能衰竭、血管痉挛、脑和心脏缺血、心肌梗死、炎症性疾病、雷诺氏病和内毒素休克以及哮喘方面具有用处。

表征谱图